<< LEO Pharma announces positive results for two Phase III AK clinical trials | New findings reveal POPG lipid can prevent RSV infection in lungs >>

Read in | English | Deutsch | 简体中文

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

Published on December 22, 2009 at 12:48 AM · No Comments

PDL BioPharma, Inc. (Nasdaq: PDLI) today announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company (NYSE: LLY) under PDL's Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details of the licensing agreement were made available.

Lilly currently holds a license to the Queen et al patents with respect to solanezumab, its humanized antibody to beta amyloid which is currently being studied to delay the progression of Alzheimer's disease.

SOURCE PDL BioPharma, Inc.

96926281-c188-448f-89a0-ab315d82fe1a|0|.0

Posted in:

Tags: Alzheimer's Disease, Antibody, beta Amyloid, Cancer, Diabetes, Diabetes Mellitus, Monoclonal Antibody, Type 1 Diabetes

Related posts

Closed-loop artificial pancreas could fight against Type 1 diabetesEngineering researchers at Rensselaer Polytechnic Institute are combining automation techniques from...
Rockland produces new Anti-NF-κB monoclonal antibodyRockland Immunochemicals has produced a new Anti-NF-κB monoclonal antibody validated by several assa...
Gene transfer reduces and stabilizes plaque and decreases inflammationA plaque-fighting gene - studied in various forms by researchers at the Cedars-Sinai Heart Institute...
ESC pleased with European Health Award recognition for Chronic Disease AllianceThe European Society of Cardiology is delighted to see the European Health Award 2010 handed to the ...
Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack neededWorking with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer...
University of California researchers awarded AAN's 2010 Potamkin PrizeThe American Academy of Neurology (AAN) is awarding its 2010 Potamkin Prize to two researchers for t...
Arsenic aids tumor imaging when joined to cancer-homing drugArsenic linked to a drug that binds to the blood vessels of cancerous tumors provides a powerful ima...
Data suggests potential target for Alzheimer's disease treatmentResearchers from Weill Cornell Medical College and Columbia University College of Physicians & Surge...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.